January 19, 2010 - Shares of GenVec Inc. (GNVC) are surging this morning as the company has hooked up with Novartis AG (NVS) to work on a treatment for Hearing Loss and Balance disorders. GenVec Inc stock is trading at $2.08, Up 19.5% in pre market. Below is a small piece of the press release.
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has entered into a research collaboration and license agreement. GenVec and Novartis will collaborate to discover and develop novel treatments for hearing loss and balance disorders. Preclinical results suggest that delivery of the atonal gene using GenVec’s innovative adenovector technology may have the potential to restore hearing and balance function.
Full Press Release
Today's Biggest Stock Market Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Stocks for 2010
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Showing posts with label gnvc. Show all posts
Showing posts with label gnvc. Show all posts
Tuesday, January 19, 2010
Tuesday, August 25, 2009
GenVec Inc. (GNVC) Receives Grant
August 25, 2009 - Shares of GenVec Inc. (GNVC) are set to open 10% higher in pre market as the company will be receiving a 2.5 million grant.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec’s vector production technology.
Funds from this grant, valued at approximately $2.5 million over three years, will be used to support the development of novel cell lines capable of producing vaccine vectors based on different human serotype groups and encoding inhibitory antigens.
“This important grant will support work to advance our cell line technology and enhance GenVec’s ability to discover and develop new adenovector-based vaccines and therapeutics,” said Dr. Doug Brough, GenVec’s Executive Director of Vector Sciences. Press Release
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec’s vector production technology.
Funds from this grant, valued at approximately $2.5 million over three years, will be used to support the development of novel cell lines capable of producing vaccine vectors based on different human serotype groups and encoding inhibitory antigens.
“This important grant will support work to advance our cell line technology and enhance GenVec’s ability to discover and develop new adenovector-based vaccines and therapeutics,” said Dr. Doug Brough, GenVec’s Executive Director of Vector Sciences. Press Release
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Subscribe to:
Posts (Atom)
